Cost Effectiveness of Cardioprotective Strategies in Patients with Aggressive Non-Hodgkin’s Lymphoma

Author： Limat Samuel   Demesmay Karine  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.25, Iss.11, 2005-01, pp. : 719-729

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel treatment strategies for aggressive non-Hodgkin’s lymphoma

By Fayad Luis   Younes Anas  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 6, 2006-04 ,pp. : 733-748

Informa Healthcare

Access to resources Recommend Favorite

Aggressive Non-Hodgkin’s Lymphoma: Economics of High-Dose Therapy

By Beard S.M.  

PharmacoEconomics, Vol. 22, Iss. 4, 2004-01 ,pp. : 207-224

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkin's Lymphoma

By Fagnoni Philippe   Milpied Noel  

PharmacoEconomics, Vol. 27, Iss. 1, 2009-01 ,pp. : 55-68

Adis International

Access to resources Recommend Favorite

Treatment advances in non-Hodgkin’s lymphoma

By Tan B.R.   Bartlett N.L.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 3, 2000-03 ,pp. : 451-465

Informa Healthcare

Access to resources Recommend Favorite

Economic assessment in the management of non-Hodgkin’s lymphoma

By van Agthoven Michel   Uyl-de Groot Carin A   Sonneveld Pieter   Hagenbeek Anton  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 12, 2004-12 ,pp. : 2529-2548

Informa Healthcare

Access to resources Recommend Favorite